Drugs giant GlaxoSmithKline and German biotech firm CureVac have struck a €150m (£130m) deal to develop next-generation COVID-19 vaccines that target several variants of the virus in one product.
Full ArticlePlan to develop new vaccine that targets COVID-19 variants in one product
Sky News
0 shares
2 views
You might like
Related news coverage
Nvidia & darpa biohybrid
Rumble
https://www.youtube.com/watch?v=0Hg7XhbXuac . No One is Talking About What Just Happened..
Advertisement
More coverage
Plan to develop new vaccine that targets COVID-19 variants in one jab
Drugs giant GlaxoSmithKline and German biotech firm CureVac have struck a €150m (£130m) deal to develop next-generation COVID-19..
Sky News